Chengdu Olymvax Biopharmaceuticals (SH:688319) Xin Lang Cai Jing·2025-11-28 02:19Core Viewpoint - Oulin Biotech's stock has experienced significant fluctuations, with a year-to-date increase of 135.66% and a recent decline in trading performance, indicating potential volatility in the market [1][2]. Company Overview - Oulin Biotech, established on December 11, 2009, and listed on June 8, 2021, is located in Chengdu, Sichuan Province. The company specializes in the research, production, and sales of human vaccines [1]. - The main revenue sources for Oulin Biotech include: Tetanus vaccine (90.99%), A and C group meningococcal polysaccharide conjugate vaccine (4.49%), Haemophilus influenzae type b conjugate vaccine (3.99%), and others (0.47%) [1]. Financial Performance - For the period from January to September 2025, Oulin Biotech reported a revenue of 507 million yuan, reflecting a year-on-year growth of 31.11%. The net profit attributable to the parent company was approximately 47.48 million yuan, showing a substantial increase of 1079.36% [2]. - Since its A-share listing, Oulin Biotech has distributed a total of 15.43 million yuan in dividends [3]. Shareholder Information - As of September 30, 2025, Oulin Biotech had 10,200 shareholders, an increase of 56.42% from the previous period. The average number of circulating shares per shareholder was 39,746, a decrease of 36.07% [2]. - Among the top ten circulating shareholders, notable positions include: Xingquan Helun Mixed A (holding 15.44 million shares), Xingquan Heyi Mixed A (holding 8.92 million shares), and Xingquan Commercial Model Mixed (LOF) A (holding 4.64 million shares, a new entry) [3].